Hyperprolactinemia in a patient with a pituitary mass can be the result of tumor production but also occurs in patients with masses that do not produce PRL but interrupt the tonic hypothalamic inhibition of PRL secretion by dopamine, including even inflammatory disorders. This evidence concerns the gene PRL and hyperprolactinemia.